ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO1201

Outcome Implications of Benzodiazepine and Opioid Co-Prescription in Kidney Transplant Recipients: A Pharmacoepidemiologic Analysis

Session Information

Category: Transplantation

  • 1902 Transplantation: Clinical

Authors

  • Lam, Ngan, University of Alberta, Edmonton, Alberta, Canada
  • Schnitzler, Mark, Saint Louis Univ, Shiloh, Illinois, United States
  • McAdams-DeMarco, Mara, Johns Hopkins, Baltimore, Maryland, United States
  • Hess, Gregory P., LDI University of Pennsylvania/Symphony Health, Wayne, Pennsylvania, United States
  • Lentine, Krista L., Saint Louis University, St. Louis, Missouri, United States
Background

Recent studies identify coprescription of benzodiazepines and opioids as a risk factor for adverse outcomes in the general population, but relationships have not been described among kidney transplant (KTx) recipients.

Methods

We examined a novel linkages of national registry data with records from a pharmaceutical claims warehouse (2008 to 2017) to characterize benzodiazepine and opioid use in the year after KTx and associations (adjusted hazard ratio, 95% LCLaHR95%UCL) with death >1 to 5 years post-KTx.

Results

Among 103,969 KTx recipients 15% filled benzodiazepines in the year after transplant: 6.3% long-acting, 7.5% short-acting, 1.8% both. Considered alone, benzodiazepine use in the first year posttransplant was associated with increased (P<0.05) mortality >1 to 5 yrs after KTx: aHR long-acting, 1.141.251.36; aHR short-acting, 1.331.441.56; aHR both, 1.411.641.91. Opioid use was higher in those who also filled benzodiazepines, especially both long- and short-acting (Fig A). Use of both medications was more common among recipients who were white, unemployed, and received prior KTx. There was also graded association of higher level opioid use with mortality that appeared additive with benzodiazepine coprescription (Fig. B). Patients who filled both classes of benzodiazepines and high-level opioids had 2.6-times mortality risk, compared to no use.

Conclusion

Benzodiazepines use is correlated with opioid fills after KTx, and these agents have additive associations on post-KTx mortality. Future work is needed to examine mechanisms of these associations and impact of reducing coprescription on improving outcomes after KTx.

Opioid Use by Benzodiazepine Use, and Associated Outcomes

Funding

  • NIDDK Support